Sign in
Not yet recruitingNo phase

Randomized Controlled Trial of Mycophenolate Mofetil Versus Steroid Therapy in Alcoholic Hepatitis

Key facts

Who runs it
Institute of Liver and Biliary Sciences, India
Where
India1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
60 people, planned
Started
20 Jan 2025
Planned end
31 Jan 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Mycophenolate Mofetil
  • Prednisone
Record updated
23 January 2025

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Adults aged 18-70 years
  • Diagnosis of Alcoholic hepatitis based on NIAAA criteria
  • MELD 20-35
  • Willing to follow up

Who cannot take part

  • Patients with contraindications to steroids
  • Patients who are on current treatment with prednisone and/or immunosuppressive me
  • Patients with hepatic/ extra hepatic malignancies
  • Patient who have severe extra hepatic organ failure
  • Patients who are HBsAg +, HIV+
  • Patients who are critically ill and are admitted to the ICU
  • If female of childbearing potential: known pregnancy, or unwilling to practice anticontraceptive measures

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Patients with acute alcoholic hepatitis will be identified based on national institute on alcohol abuse and alcoholism (NIAAA) will be identified, MELD score will be calculated, patents with MELD score between 20-35 will be randomized to two groups. Group A (intervention arm) will be receiving Mycofenolate mofetil at a dose of 750 mg twice daily and group B will be receiving steroid as per existing guidelines in a dose of 40 mg per day. Both the groups will be followed up for 90 days with assessment done at 4th, 7th and 28th day. Any significant event in addition will also be noted. Patients in group A will be also be monitored for development of complications like cytopenia due to Mycofenolate mofetil and infections will be monitored in both groups. Steroids will be stopped in the non-responders in group B based on Lille score at 4th and 7th day. The outcome variables of interest and to be measured are survival at 28 days and 90 days, clinical outcomes, including hospitalization and liver related outcomes.

The 2 groups in the trial

  • mycophenolate mofetilTreatment being tested

    Intervention arm in the study will receive MMF at a dose of 750 mg twice daily for a period of 28 days.

  • Steroid prednisoloneExisting treatment, for comparison

    steroid at a dose of 40 mg for 28 days.

    Treatment: Prednisone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Fit questions
Built from NCT06789315, who can take part
Record updated
23 January 2025